Cargando…

Updated EUCAST Clinical Breakpoints against Aspergillus, Implications for the Clinical Microbiology Laboratory

Azole resistance poses a problem for the management of patients with invasive aspergillosis. Former species are in fact groups of closely related species (or complexes); cryptic species frequently show high antifungal resistance. The European Committee on Antimicrobial Susceptibility Testing (EUCAST...

Descripción completa

Detalles Bibliográficos
Autor principal:	Guinea, Jesús
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7762142/ https://www.ncbi.nlm.nih.gov/pubmed/33291313 http://dx.doi.org/10.3390/jof6040343

Ejemplares similares

A Pragmatic Approach to Susceptibility Classification of Yeasts without EUCAST Clinical Breakpoints
por: Astvad, Karen Marie Thyssen, et al.
Publicado: (2022)

647. Adoption of the updated fluoroquinolones breakpoints for Gram negative bacteria in clinical microbiology laboratories
por: Sfeir, Maroun M
Publicado: (2020)

Re: In the name of common sense: EUCAST breakpoints and potential pitfalls. National dissemination of EUCAST guidelines is a shared responsibility
por: Kahlmeter, Gunnar, et al.
Publicado: (2020)

Impact of CLSI and EUCAST breakpoint discrepancies on reporting of antimicrobial susceptibility and AMR surveillance
por: Cusack, T.P., et al.
Publicado: (2019)

Ceftaroline Susceptibility among Isolates of MRSA: A Comparison of EUCAST and CLSI Breakpoints
por: Sachu, Arun
Publicado: (2023)

Interpretation of Antimicrobial Susceptibility Testing Using European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Clinical and Laboratory Standards Institute (CLSI) Breakpoints: Analysis of Agreement
por: Gaur, Priyanka, et al.
Publicado: (2023)

Molecular mechanisms of acquired antifungal drug resistance in principal fungal pathogens and EUCAST guidance for their laboratory detection and clinical implications
por: Rogers, Thomas R, et al.
Publicado: (2022)

1269. Differences in Interpretative Breakpoints Between CLSI, FDA and EUCAST Impact Reporting of Susceptibility and Resistance to Cefiderocol
por: Yamano, Yoshinori, et al.
Publicado: (2020)

Spectrophotometric detection of azole-resistant Aspergillus fumigatus with the EUCAST broth microdilution method: is it time for automated MIC reading of EUCAST antifungal susceptibility testing of Aspergillus species?
por: Meletiadis, Joseph, et al.
Publicado: (2022)

Does the adoption of EUCAST susceptibility breakpoints affect the selection of antimicrobials to treat acute community-acquired respiratory tract infections?
por: Marchese, Anna, et al.
Publicado: (2012)

Clinical Failures of Linezolid and Implications for the Clinical Microbiology Laboratory
por: Potoski, Brian A., et al.
Publicado: (2002)

Laboratory Automation in Clinical Microbiology
por: Burckhardt, Irene
Publicado: (2018)

New definitions of susceptibility categories EUCAST 2019: clinic application
por: Díaz, Sandra G. Nabal, et al.
Publicado: (2022)

In Vitro Activity of Ibrexafungerp against a Collection of Clinical Isolates of Aspergillus, Including Cryptic Species and Cyp51A Mutants, Using EUCAST and CLSI Methodologies
por: Rivero-Menendez, Olga, et al.
Publicado: (2021)

Instruction videos from EUCAST
Publicado: (2020)

Comparison of the Micronaut-AM System and the EUCAST Broth Microdilution Reference Method for MIC Determination of Four Antifungals against Aspergillus fumigatus
por: Gyurtane Szabo, Nikolett, et al.
Publicado: (2023)

In vitro antifungal susceptibilities of six antifungal drugs against clinical Candida glabrata isolates according to EUCAST
por: Fatahinia, Mahnaz, et al.
Publicado: (2020)

Clinically and Microbiologically Derived Azithromycin Susceptibility Breakpoints for Salmonella enterica Serovars Typhi and Paratyphi A
por: Parry, Christopher M., et al.
Publicado: (2015)

1597. Evaluation of Ceftaroline Resistance (CPT-R) in Chile Across Time and a Comparison of CLSI vs. EUCAST Breakpoints in Methicillin-Resistant Staphylococcus aureus (MRSA)
por: Khan, Ayesha, et al.
Publicado: (2019)

Usefulness of EUCAST rapid antibiotic susceptibility breakpoints and screening cut-off values directly from blood cultures for the inference of β-lactam resistance mechanisms in Enterobacterales
por: Cerrudo, V, et al.
Publicado: (2023)

EUCAST rapid antimicrobial susceptibility testing (RAST) in blood cultures: validation in 55 European laboratories
por: Åkerlund, Anna, et al.
Publicado: (2020)

2113. Evaluation of Isavuconazole Activity against Aspergillus fumigatus Causing Invasive Infections Worldwide Using the New CLSI Clinical Breakpoints
por: Carvalhaes, Cecilia G, et al.
Publicado: (2023)

Impact of Tigecycline’s MIC in the Outcome of Critically Ill Patients with Carbapenemase-Producing Klebsiella pneumoniae Bacteraemia Treated with Tigecycline Monotherapy—Validation of 2019′s EUCAST Proposed Breakpoint Changes
por: Papadimitriou-Olivgeris, Matthaios, et al.
Publicado: (2020)

Molecular Identification and Antifungal Susceptibility Patterns of Clinical Dermatophytes Following CLSI and EUCAST Guidelines
por: Dabas, Yubhisha, et al.
Publicado: (2017)

EUCAST Susceptibility Testing of Isavuconazole: MIC Data for Contemporary Clinical Mold and Yeast Isolates
por: Jørgensen, Karin Meinike, et al.
Publicado: (2019)

Evidence for Establishing the Clinical Breakpoint of Cefquinome against Haemophilus Parasuis in China
por: Mi, Kun, et al.
Publicado: (2021)

Application and Perspectives of MALDI–TOF Mass Spectrometry in Clinical Microbiology Laboratories
por: Torres-Sangiao, Eva, et al.
Publicado: (2021)

Raising the Bar: Improving Antimicrobial Resistance Detection by Clinical Laboratories by Ensuring Use of Current Breakpoints
por: Simner, Patricia J, et al.
Publicado: (2022)

Challenges in microbiological diagnosis of invasive Aspergillus infections
por: Alanio, Alexandre, et al.
Publicado: (2017)

Automated parasitological diagnosis in clinical microbiology laboratories
por: Fernández-Rivas, Gema, et al.
Publicado: (2021)

Advances in Rapid Identification and Susceptibility Testing of Bacteria in the Clinical Microbiology Laboratory: Implications for Patient Care and Antimicrobial Stewardship Programs
por: Maurer, Florian P., et al.
Publicado: (2017)

Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates
por: Pfaller, Michael A., et al.
Publicado: (2016)

The Influence of Medium Composition on EUCAST and Etest Antifungal Susceptibility Testing
por: Vahedi-Shahandashti, Roya, et al.
Publicado: (2023)

Introducing New Laboratory-Developed Molecular Methods in the Clinical Microbiology Laboratories
por: Pouladfar, Gholamreza
Publicado: (2012)

Comparison between EUCAST Broth Microdilution and MIC Strip Test in Defining Isavuconazole In Vitro Susceptibility against Candida and Rare Yeast Clinical Isolates
por: Calvo, Maddalena, et al.
Publicado: (2023)

Clinical laboratory diagnostics in dentistry: Application of microbiological methods
por: Claesson, Rolf, et al.
Publicado: (2022)

Clinical and Microbiological Characterization of Invasive Pulmonary Aspergillosis Caused by Aspergillus lentulus in China
por: Yu, Shu-Ying, et al.
Publicado: (2020)

Time to switch from CLSI to EUCAST? A Southeast Asian perspective
por: Cusack, T.P., et al.
Publicado: (2019)

342. Multicenter Evaluation of Fosfomycin MIC Results for Enterobacterales Using EUCAST V11 Breakpoints (i.v. and oral for uncomplicated UTI only, E. coli) on MicroScan Dried Gram Negative MIC Panels
por: Garner, Omai, et al.
Publicado: (2022)

1599. Clinical Outcomes for Patients Treated with Fluoroquinolones for Bacteremia Caused by Enterobacteriaceae Reclassified as Not Susceptible by Updated CLSI Breakpoints
por: Fleischner, Zachary, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_iu9os5v3b3mme689ugpta0jeef